{"id":"arq-151-cream-0-15","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"}]},"_chembl":{"chemblId":"CHEMBL4303449","moleculeType":"Small molecule","molecularWeight":"552.44"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting PDE4, ARQ-151 increases intracellular cAMP levels, which leads to reduced production of pro-inflammatory cytokines and mediators, thereby alleviating inflammation and associated symptoms.","oneSentence":"ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:34:57.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT04804605","phase":"PHASE3","title":"Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-25","conditions":"Atopic Dermatitis Eczema","enrollment":1220},{"nctId":"NCT04773587","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-01-27","conditions":"Atopic Dermatitis Eczema","enrollment":654},{"nctId":"NCT04773600","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-24","conditions":"Atopic Dermatitis Eczema","enrollment":683},{"nctId":"NCT04156191","phase":"PHASE1","title":"Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-23","conditions":"Atopic Dermatitis (Eczema)","enrollment":101},{"nctId":"NCT03916081","phase":"PHASE2","title":"Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-05-31","conditions":"Atopic Dermatitis","enrollment":136},{"nctId":"NCT03638258","phase":"PHASE2","title":"The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-09-21","conditions":"Plaque Psoriasis","enrollment":331},{"nctId":"NCT03392168","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2017-12-11","conditions":"Psoriasis","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARQ-151 cream 0.15%","genericName":"ARQ-151 cream 0.15%","companyName":"Arcutis Biotherapeutics, Inc.","companyId":"arcutis-biotherapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses. Used for Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}